

SOLIGENIX, INC.  
Form 8-K  
August 24, 2010

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 23, 2010

Commission File No. 000-16929

---

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

DELAWARE  
(State or other jurisdiction of  
incorporation or  
organization)

41-1505029  
(I.R.S. Employer  
Identification Number)

29 Emmons Drive,  
Suite C-10  
Princeton, NJ  
(Address of principal  
executive offices)

08540  
(Zip Code)

(609) 538-8200  
(Issuer's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: SOLIGENIX, INC. - Form 8-K

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On August 23, 2010, Soligenix, Inc. (the “Company”) issued a press release announcing that it had been awarded a three year \$1.2 million clinical research grant by the Office of Orphan Products Development of the U.S. Food and Drug Administration pursuant to its Orphan Products Development Program. The grant will be used to defray a significant portion of the costs associated with the conduct of the Company’s ongoing, confirmatory, Phase 3 clinical trial of orBec® in the treatment of acute gastrointestinal Graft-versus-Host-Disease. A copy of the press release is attached as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Other Exhibits.

(d) Exhibits.

Exhibit No.	Description
----------------	-------------

99.1	Press release issued by the Company on August 23, 2010.
------	---------------------------------------------------------

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Soligenix, Inc.

August 24, 2010

By: /s/ Christopher J. Schaber  
Christopher J. Schaber, Ph.D.  
President and Chief Executive  
Officer  
(Principal Executive Officer)

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued by the Company on August 23, 2010.